ZA200402729B - Pharmaceutical formulation comprising (R) -bicalutamide. - Google Patents

Pharmaceutical formulation comprising (R) -bicalutamide.

Info

Publication number
ZA200402729B
ZA200402729B ZA200402729A ZA200402729A ZA200402729B ZA 200402729 B ZA200402729 B ZA 200402729B ZA 200402729 A ZA200402729 A ZA 200402729A ZA 200402729 A ZA200402729 A ZA 200402729A ZA 200402729 B ZA200402729 B ZA 200402729B
Authority
ZA
South Africa
Prior art keywords
bicalutamide
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
ZA200402729A
Other languages
English (en)
Inventor
Julie Kay Cahill
Nicola Frances Bateman
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of ZA200402729B publication Critical patent/ZA200402729B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200402729A 2001-10-15 2004-04-07 Pharmaceutical formulation comprising (R) -bicalutamide. ZA200402729B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103424A SE0103424D0 (sv) 2001-10-15 2001-10-15 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
ZA200402729B true ZA200402729B (en) 2005-01-13

Family

ID=20285650

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200402729A ZA200402729B (en) 2001-10-15 2004-04-07 Pharmaceutical formulation comprising (R) -bicalutamide.

Country Status (19)

Country Link
US (1) US20060058381A1 (xx)
EP (1) EP1439823A1 (xx)
JP (1) JP3639587B2 (xx)
KR (1) KR20050035163A (xx)
CN (1) CN1571658A (xx)
AR (1) AR036877A1 (xx)
BR (1) BR0213248A (xx)
CA (1) CA2462219A1 (xx)
CO (1) CO5580755A2 (xx)
HU (1) HUP0401369A3 (xx)
IL (1) IL161306A0 (xx)
IS (1) IS7219A (xx)
MX (1) MXPA04003520A (xx)
NO (1) NO20041485L (xx)
PL (1) PL368226A1 (xx)
RU (1) RU2004115023A (xx)
SE (1) SE0103424D0 (xx)
WO (1) WO2003032950A1 (xx)
ZA (1) ZA200402729B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL365746A1 (en) * 2001-02-27 2005-01-10 Astrazeneca Ab Pharmaceutical formulation comprising bicalutamide
EP2165703A3 (en) 2004-01-20 2012-03-28 Novartis Pharma AG Direct compression formulation and process
JP2008531531A (ja) * 2005-02-23 2008-08-14 アストラゼネカ アクチボラグ 方法
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP3023433A1 (en) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
CN101987086B (zh) * 2009-08-03 2012-07-18 北京化工大学 一种超细比卡鲁胺口服片剂及其制备方法
BR112014001440A2 (pt) * 2011-07-18 2017-02-21 Tokai Pharmaceuticals Inc novas composições e métodos para o tratamento de câncer de próstata
CN109897004A (zh) 2012-09-11 2019-06-18 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
EP3226843B1 (en) 2014-12-05 2021-05-26 Aragon Pharmaceuticals, Inc. Anticancer compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629237A (en) * 1968-09-12 1971-12-21 Shinetsu Chemical Co Compositions useful as enteric coatings and method for preparing acid phthalates of cellulose ethers for them
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
EP0748220A4 (en) * 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
PL365746A1 (en) * 2001-02-27 2005-01-10 Astrazeneca Ab Pharmaceutical formulation comprising bicalutamide
ATE324886T1 (de) * 2001-04-02 2006-06-15 Astrazeneca Ab Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp

Also Published As

Publication number Publication date
HUP0401369A2 (hu) 2004-11-29
HUP0401369A3 (en) 2006-05-29
IS7219A (is) 2004-04-14
US20060058381A1 (en) 2006-03-16
BR0213248A (pt) 2004-09-28
WO2003032950A1 (en) 2003-04-24
MXPA04003520A (es) 2004-07-23
IL161306A0 (en) 2004-09-27
JP3639587B2 (ja) 2005-04-20
CO5580755A2 (es) 2005-11-30
NO20041485L (no) 2004-04-13
PL368226A1 (en) 2005-03-21
CN1571658A (zh) 2005-01-26
CA2462219A1 (en) 2003-04-24
SE0103424D0 (sv) 2001-10-15
EP1439823A1 (en) 2004-07-28
KR20050035163A (ko) 2005-04-15
RU2004115023A (ru) 2005-04-10
JP2004521963A (ja) 2004-07-22
AR036877A1 (es) 2004-10-13

Similar Documents

Publication Publication Date Title
MXPA03006775A (es) Formulacion farmaceutica.
MXPA03007641A (es) Formulacion farmaceutica.
MXPA03007215A (es) Formulaciones farmaceuticas.
GB0118689D0 (en) Pharmaceutical formulation
AP2003002907A0 (en) Liquid pharmaceutical composition.
AU2002257582A1 (en) Pharmaceutical formulation
PL366432A1 (en) Pharmaceutical formulation
GB0104534D0 (en) Pharmaceutical combination
GB0121715D0 (en) Pharmaceutical formulations
ZA200206779B (en) Solid formulation.
GB0120701D0 (en) Pharmaceutical formulations
GB0103638D0 (en) Pharmaceutical formulations
ZA200402729B (en) Pharmaceutical formulation comprising (R) -bicalutamide.
GB2380129B (en) Pharmaceutical formulations
GB0105560D0 (en) Pharmaceutical formulations
GB0124523D0 (en) Pharmaceutical combination
GB0129270D0 (en) Pharmaceutical combination
GB0129397D0 (en) Pharmaceutical combination
ZA200110500B (en) Pharmaceutical composition.
GB0129395D0 (en) Pharmaceutical combination
MXPA03007318A (es) Composicion farmaceutica.
GB0124455D0 (en) Pharmaceutical formulations
ZA200306383B (en) Pharmaceutical formulation comprising bicalutamide.
ZA200402731B (en) Pharmaceutical formulation.
ZA200110501B (en) Pharmaceutical composition.